- Home
- TBBK vs RCKT Comparison
TBBK vs RCKT Comparison
Compare TBBK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBBK | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 340.9M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | TBBK | RCKT |
|---|---|---|
| Price | $68.20 | $3.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $68.00 | $29.12 |
| AVG Volume (30 Days) | 561.3K | ★ 2.0M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.10 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | ★ $523,163,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.53 | N/A |
| P/E Ratio | $14.40 | ★ N/A |
| Revenue Growth | ★ 10.84 | N/A |
| 52 Week Low | $40.51 | $2.19 |
| 52 Week High | $81.65 | $13.35 |
Technical Indicators
Market Signals| Indicator | TBBK | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 46.08 |
| Support Level | $66.85 | $3.30 |
| Resistance Level | $70.44 | $3.57 |
| Average True Range (ATR) | 1.93 | 0.18 |
| MACD | 0.46 | -0.01 |
| Stochastic Oscillator | 65.34 | 22.81 |
Price Performance
Historical ComparisonAbout TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.